The effects of sequential treatment as a first-line therapy for Helicobacter pylori eradication

There is no effective eradication regimen for Helicobacter pylori (HP) in Turkey. Recent studies have shown that sequential therapy may be superior to the standard triple therapy in terms of the eradication of HP. In this study, we aim to assess the efficacy of a 14-day sequential treatment regimen as a first-line therapy for HP eradication. Materials and methods: This is a prospective, open-label, single-centre study. The study involved 86 consecutive patients with nonulcer dyspepsia. All patients were randomly assigned into 2 study groups at a 2:1 ratio using random sampling numbers. The first group of patients were administered a sequential treatment: pantoprazole 2 × 40 mg and amoxicillin 2 × 1000 mg for the first 7 days and pantoprazole 2 × 40 mg, metronidazole 2 × 500 mg, and tetracycline 4 × 500 mg for the remaining 7 days. The second group of patients were administered pantoprazole 2 × 40 mg, amoxicillin 2 × 1000 mg, and clarithromycin 2 × 500 mg (PAC) for 14 days. Eradication was defined as the absence HP as assessed with the (14-C) urea breath test 4 weeks after the end of the antimicrobial therapy. Results: The eradication rate in the sequential group was 56.1% for the ITT analysis and 57.1% for the PP analysis, the eradication rate of the PAC group was 58.6 % for both PP and ITT analysis. There was a statistically significant difference between the eradication rates of the groups for both PP and ITT analysis. There was no statistically significant difference in the adverse effects encountered in both groups (10.5% versus 13.8% P > 0.05). Conclusion: These results suggest that a 14-day sequential eradication regimen is not effective as a first-line therapy for HP eradication.

Anahtar Kelimeler:

Key words: Sequential treatment; helicobacter pylori eradication

The effects of sequential treatment as a first-line therapy for Helicobacter pylori eradication

Keywords:

Key words: Sequential treatment; helicobacter pylori eradication,

PDF

___

1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clinical Microbiology Reviews 1997; 10: 720-741.
2. Wong BCY, Lam SK, Lai KC, Hu WH, Ching CK, Ho J et al. Triple therapy for Helicobacter pylori eradication is more eff ective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Th er 1999; 13: 303-309.
3. Bayerdörff er E, Neubauer A, Rudolph B, Th iede C, Lehn N, Eidt S et al. Regression of primary gastric lymphoma of mucosaassociated lymphoid tissue type aft er cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594.
4. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection – Th e Maastricht III consensus report. Gut 2007; 56: 772-81.
5. Kadayıfcı A, Buyukhatipoglu H, Savas M Cemil, Simsek I. Eradication of Helicobacter pylori with triple therapy: An epidemiologic analysis of trends in Turkey over 10 years. Clin Th er 2006; 11: 1960-1966.
6. Uygun A, Kadayıfçı A, Yeşilova Z. Hp eradikasyonunda lansoprazol ve pantoprazol içeren üçlü rejimlerin etkinliginin karşılaştırılması (Comparison of eff ectiveness of lansoprazole and pantoprazole based triple therapy in Helicobacter pylori eradication). Turk J Gastroenterol 2003; (Suppl): PB.08/33)
7. Güliter S, Keleş H, Özkurt ZN, Cengiz DU, Kolukısa E. Can lansoprazole, amoxicillin and clarithromycin combination still be used as a fi rst-line therapy for eradication of Helicobacter pylori? Turk J Gastroenterol 2005; 16: 29-33.
8. Ertaş E, Tüzün A, Özden A. Helicobacter pylori pozitif fonksiyonel dispepside 7 ve 14 günlük pantoprazol, klaritromisin, amoksisilin kombinasyon tedavisinin eradikasyon etkinliginin ve eradikasyonun dispeptik semptomlar üzerine etkilerinin degerlendirilmesi. (Eff ectiveness of 7 and 14 days pantoprazole, amoxicillin, clarithromycin combination treatments in Helicobacter pylori positive functional dyspepsia). Turk J Gastroenterol 2004; (Suppl): PB.08/18.
9. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Th er 2003; 17: 719-26.
10. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 17: 148: 923-31.
11. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Th er 2009; 34: 41-53.
12. Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Th er 2008; 30: 528-34.
13. Sezgin O, Altintaş E, Nayir E, Uçbilek E. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter. 2007; 12: 629-32.
14. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Eff ect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.
15. Sezgin O, Aslan G, Altintaş E, Tezcan S, Serin MS, Emekdaş G. Detection of point mutations on 23S rRNA of Helicobacter pylori and resistance to clarithromycin with PCR-RFLP in gastric biopsy specimens in Mersin, Turkey. Turk J Gastroenterol 2008; 19: 163-7.
16. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006; 144: 94-100.
17. Agel E, Durmaz B, Tevfi k MR, Asgın R. Th e isolation rate and antibiotic resistant pattern of Helicobacter pylori in dyspeptic patients. Turk J Med Sci 2000; 30: 143-146.
18. Goral V, Fadile YZ, Gül K. Helikobakter pilori infeksiyonunda antibiyotik direnci. T. Klin Gastroenterohepatol 2000; 11: 87- 92.
19. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272- 1277.
20. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafl oxacin in Th e Netherlands. J Antimicrob Chemother 1999; 43: 511-515.
21. de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients: a personal viewpoint. J Clin Gastroenterol 1996; 22: 313-316.
22. Demir M, Göktürk S, Oztürk NA, Serin E, Yilmaz U. Bismuthbased fi rst-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion 2010; 82: 47-53.